Borrelia burgdorferi Vaccines
Creative Biolabs is a leading global pharmaceutical company which focuses on the field of vaccine development. With our extensive experience and advanced platform, we have won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in vaccine development services for Borrelia burgdorferi. We guarantee the finest results for our customers all over the world.
Borrelia burgdorferi, a member of Spirochete family, is a bacterium whose normal reservoir is a number of small mammals, lizards, and birds. It normally cannot lead to disease, but it causes Lyme disease in human. Lyme disease is the most common vector-borne infectious illness in the USA and Europe. The clinical symptoms include an erythema migrans rash, fever, headache, fatigue, an influenza-like illness, as well as arthritis. The data suggest that it is epidemic and fatal to public health around the globe. Recent research demonstrate that vaccines targeted on B. burgdorferi infection and disease have been studies in several different animal models. A recombinant OspA protein has been identified to widely used in developing vaccines to B. burgdorferi prevention.
Fig.1 Regulation Gene Expression in B. burgdorferi. (Singh S.K, et al., 2004)
The Borrelia burgdorferi Vaccines
The threat of continued Lyme disease epidemics has spurred efforts to develop B. burgdorferi vaccines. Whole-cell vaccines are currently available for veterinary use but not for human, owing to the limited protection for B. burgdorferi infection. A single dose of a whole-cell vaccine has been evaluated in many animal models, such as mouse and hamster. The results suggest that a single dose of this inactivated whole cells can only provide 75% to 86% protection in hamsters. The efficacy of this vaccine should be further improved.
As for human B. burgdorferi vaccine development, a live attenuated vaccine based on outer surface protein A (OspA) has been developed, but the safety and the efficacy of this vaccine have not yet been verified. The studies demonstrate that this recombinant OspA vaccine can provide 80% effective in a large-scale human trial conducted on 14 sites in areas of the United States. Further studies need to be done to identify new candidates which are more effective and safer for B. burgdorferi vaccines.
The B. burgdorferi Strains for Vaccine Development
In order to develop a more effective B. burgdorferi vaccine, candidates should be broadly applicable to protection against B. burgdorferi infections caused by all strains. Many strains (B. burgdorferi B31-A3, B. burgdorferi N40 D10/E9, B. garinii PBr, B. burgdorferi B31-A3 p66cp and deletion of p66 in B. burgdorferi B31-A3) have been studies the protective, antibody-mediated immunity in mice models. The results show that live attenuated B. burgdorferi strains are safe and effective against B. burgdorferi. Meanwhile, proteins produced by effective B. burgdorferi strains, such as P66, could be used as candidates for B. burgdorferi vaccine development.
Our Services for Borrelia burgdorferi Vaccines
Our platform equipped with state-of-the-art facilities and highly experienced staff are available in order to assist in all areas of B. burgdorferi vaccine project. We have integrated high-quality services which are based in America and span the entire development chain from discovery to commercialization. Our company offers the best guarantee in the industry of B. burgdorferi vaccine development and has successfully provided a series of B. burgdorferi vaccine development services for our worldwide clients.
- Fast turnaround time
- Customized vaccine development services
- Efficient and cost-effective vaccine service
Creative Biolabs is a professional vaccine development expert with extensive experience in vaccine design, immunogenicity evaluation, safety evaluation, and production process optimization. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.
Reference
- Singh S.K, et al. (2004). “Molecular survival strategies of the Lyme disease spirochete Borrelia burgdorferi.” Lancet Infect Dis. 4(9), 575-83.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
